Your browser doesn't support javascript.
loading
Chinese herbal medicine may reduce major adverse cardiovascular events in patients with dialysis hypotension: A taiwan nationwide cohort study.
Tsai, Ming-Yen; Huang, Po-Yu; Lee, Wen-Chin; Cheng, Ben-Chung; Tsai, Fuu-Jen; Liu, Chun-Ting.
Afiliación
  • Tsai MY; Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan.
  • Huang PY; Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan.
  • Lee WC; Kaohsiung Municipal Feng Shan Hospital, Under the Management of Chang Gung Medical Foundation, Kaohsiung, 830025, Taiwan.
  • Cheng BC; Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University, Kaohsiung, 83301, Taiwan.
  • Tsai FJ; Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University, Kaohsiung, 83301, Taiwan.
  • Liu CT; School of Chinese Medicine, Department of Medical Research, College of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan.
J Tradit Complement Med ; 14(5): 550-557, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39262661
ABSTRACT

Background:

The association between Chinese herbal medicine (CHM) and the risk of developing major adverse cardiovascular events (MACEs) in patients with dialysis hypotension is unclear and has not yet been investigated. This study aimed to determine whether CMH intervention could reduce the risk of MACEs in patients with dialysis hypotension.

Methods:

The study data from the Taiwan National Health Insurance Research Database were analyzed to clarify this association. For this study, a case-control design with a cohort of patients who received hemodialysis (HD) from 2008 to 2018, 20 295 HD patients who had received blood pressure (BP) raising drugs were identified. After 11 frequency-matching, 730 patients were identified as CHM users and CHM non-users. Vascular access revision/reconstruction and MACEs were observed as the main outcomes during the follow-up period.

Results:

The occurrence of vascular access revision/reconstruction in HD patients receiving BP raising drugs was associated with a 0.34-fold lower risk in CHM users than in CHM non-users [adjusted hazard ratio (aHR) = 0.34, 95% confidence interval (CI) = 0.26, 0.45]. The occurrences of MACEs in HD patients receiving BP raising drugs was associated with a 0.41-fold lower risk in CHM users than in CHM non-users (aHR = 0.41, 95% CI = 0.33, 0.51). A markedly predominant effect was observed in those receiving CHM for more than 180 days (aHR = 0.32; 95% CI = 0.22, 0.45).

Conclusion:

The findings revealed lower vascular access dysfunction and MACEs risk correlated with the use of CHM treatment among HD patients who received BP raising drugs.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Tradit Complement Med Año: 2024 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Tradit Complement Med Año: 2024 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Países Bajos